DCL Stock Overview
Cuu Long Pharmaceutical Joint Stock Company manufactures and distributes pharmaceutical products primarily in Vietnam.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cuu Long Pharmaceutical Joint Stock Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₫27,300.00 |
| 52 Week High | ₫29,300.00 |
| 52 Week Low | ₫21,700.00 |
| Beta | 0.82 |
| 1 Month Change | 13.28% |
| 3 Month Change | 10.30% |
| 1 Year Change | 18.70% |
| 3 Year Change | -11.36% |
| 5 Year Change | 36.50% |
| Change since IPO | 47.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| DCL | VN Pharmaceuticals | VN Market | |
|---|---|---|---|
| 7D | 5.0% | -1.3% | 1.0% |
| 1Y | 18.7% | 15.7% | 14.9% |
Return vs Industry: DCL exceeded the VN Pharmaceuticals industry which returned 15.7% over the past year.
Return vs Market: DCL exceeded the VN Market which returned 14.9% over the past year.
Price Volatility
| DCL volatility | |
|---|---|
| DCL Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in VN Market | 7.0% |
| 10% least volatile stocks in VN Market | 2.4% |
Stable Share Price: DCL has not had significant price volatility in the past 3 months.
Volatility Over Time: DCL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 930 | Hai Luong | dcl.com.vn |
Cuu Long Pharmaceutical Joint Stock Company manufactures and distributes pharmaceutical products primarily in Vietnam. The company offers analgesic, anti-biotic, anti-histamine, anti-inflammatory, anti-virus, cardiovascular, corticosteroid, cough, dermatology, gastrointestinal, musculoskeletal, and vitamin medicines, as well as capsules and medical equipment. It provides its products under various brands to hospitals through its distribution network, including branches and distributors.
Cuu Long Pharmaceutical Joint Stock Company Fundamentals Summary
| DCL fundamental statistics | |
|---|---|
| Market cap | ₫1.99t |
| Earnings (TTM) | ₫61.72b |
| Revenue (TTM) | ₫1.14t |
32.3x
P/E Ratio1.7x
P/S RatioIs DCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCL income statement (TTM) | |
|---|---|
| Revenue | ₫1.14t |
| Cost of Revenue | ₫934.03b |
| Gross Profit | ₫209.91b |
| Other Expenses | ₫148.20b |
| Earnings | ₫61.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 844.97 |
| Gross Margin | 18.35% |
| Net Profit Margin | 5.40% |
| Debt/Equity Ratio | 42.0% |
How did DCL perform over the long term?
See historical performance and comparison